Parabilis Medicines (PBLS) said Thursday it has closed its upsized initial public offering of about 38.5 million shares, including the full exercise of an overallotment option, at $20.00 each.
The clinical-stage biopharmaceutical company also said it has closed its sale of nearly 4.2 million at $18.00 per share in a private placement to Regeneron Pharmaceuticals.
The stock began trading on Nasdaq on June 10.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.